Accumulation of HIV drug resistance mutations in patients failing first-line antiretroviral treatment in South Africa.
暂无分享,去创建一个
[1] J. Eron,et al. Second‐line treatment in the Malawi antiretroviral programme: high early mortality, but good outcomes in survivors, despite extensive drug resistance at baseline * , 2010, HIV medicine.
[2] D. Kuritzkes,et al. Outcomes after virologic failure of first-line ART in South Africa , 2010, AIDS.
[3] Ian Sanne,et al. Varied Patterns of HIV-1 Drug Resistance on Failing First-Line Antiretroviral Therapy in South Africa , 2010, Journal of acquired immune deficiency syndromes.
[4] A. Kamali,et al. Affordable in-house antiretroviral drug resistance assay with good performance in non-subtype B HIV-1. , 2010, Journal of virological methods.
[5] K. Ruxrungtham,et al. Treatment outcomes and plasma level of ritonavir-boosted lopinavir monotherapy among HIV-infected patients who had NRTI and NNRTI failure , 2009, AIDS research and therapy.
[6] R. Chaisson,et al. Viremia, resuppression, and time to resistance in human immunodeficiency virus (HIV) subtype C during first-line antiretroviral therapy in South Africa. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[7] D. Richman,et al. Update of the drug resistance mutations in HIV-1: December 2009. , 2009, Topics in HIV medicine : a publication of the International AIDS Society, USA.
[8] B. Clotet,et al. Rate of accumulation of thymidine analogue mutations in patients continuing to receive virologically failing regimens containing zidovudine or stavudine: implications for antiretroviral therapy programs in resource-limited settings. , 2009, The Journal of infectious diseases.
[9] Sabine Yerly,et al. Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis. , 2009, The Lancet. Infectious diseases.
[10] N. Parkin,et al. The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy , 2009, AIDS.
[11] C. Delaugerre,et al. Protease Inhibitor Resistance Analysis in the MONARK Trial Comparing First-Line Lopinavir-Ritonavir Monotherapy to Lopinavir-Ritonavir plus Zidovudine and Lamivudine Triple Therapy , 2009, Antimicrobial Agents and Chemotherapy.
[12] Elena Losina,et al. HIV type-1 clade C resistance genotypes in treatment-naive patients and after first virological failure in a large community antiretroviral therapy programme , 2009, Antiviral therapy.
[13] H. Gunthard,et al. Update of the Drug Resistance Mutations in HIV-1. , 2008, Topics in HIV medicine : a publication of the International AIDS Society, USA.
[14] D. Burton,et al. The therapeutic phase I trial of the recombinant native HIV-1 Tat protein , 2008, AIDS.
[15] B. Walker,et al. Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[16] V. DeGruttola,et al. The reverse transcriptase 67N 70R 215Y genotype is the predominant TAM pathway associated with virologic failure among HIV type 1C-infected adults treated with ZDV/ddI-containing HAART in southern Africa. , 2007, AIDS research and human retroviruses.
[17] R. Chaisson,et al. Adherence to Nonnucleoside Reverse Transcriptase InhibitorBased HIV Therapy and Virologic Outcomes , 2007, Annals of Internal Medicine.
[18] S. Staszewski,et al. Evolution of Resistance Mutations during Low-Level Viral Replication in HIV-1–Infected Patients Treated with Zidovudine/Lamivudine/Abacavir as a First-Line Regimen , 2007, Antiviral therapy.
[19] Tulio de Oliveira,et al. An automated genotyping system for analysis of HIV-1 and other microbial sequences , 2005, Bioinform..
[20] Colombe Chappey,et al. Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates. , 2003, The Journal of infectious diseases.
[21] E. De Clercq,et al. Prevalence and Characteristics of Multinucleoside-Resistant Human Immunodeficiency Virus Type 1 among European Patients Receiving Combinations of Nucleoside Analogues , 2000, Antimicrobial Agents and Chemotherapy.
[22] R. Wood,et al. Bmc Infectious Diseases Risk Factors for Poor Virological Outcome at 12 Months in a Workplace-based Antiretroviral Therapy Programme in South Africa: a Cohort Study , 2022 .